IPHA's logo.
Ticker Symbol: IPHA

Innate Pharma - ADR

$5.29 - 02-12-2024 4 p.m. ET

Exchange: NASDAQ Country: France Currency: USD Asset Type: ADR CIK:0001598599

Company Profile

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 117 avenue de Luminy
CEO: Mondher Mahjoubi
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $2.60
Change: $0.01 ( 0.39%)
Days Range: $2.48 - $2.60
Beta: -
52wk. High: $3.97
52wk. Low: $1.90
Ytd. Change -30.18%
50 Day Moving Average: $2.65
200 Day Moving Average: $2.94
Shares Outstanding: 80645333

Valuation

Market Cap: 20.9B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A